05/29/2026 06:00
Samsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Vial Across Europe, to Treat Ophthalmic Conditions

Samsung Bioepis Co., Ltd. today announced the launch of OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea1 (aflibercept), across Europe, starting today. OPUVIZ marks the fifth biosimilar product to be directly commercialized by Samsung Bioepis. It builds on other key biosimilar milestones in Europe this year, including the initiation of direct commercialization of BYOOVIZ™ (ranibizumab) 10 mg/mL solution for injection in a vial, as well as the launch of XBRYK™ ...

BuildOps Expands OpsAI Across the Entire Contracting Operation as AI Use Climbs 17x in a Year

Technicians ran more than 100,000 equipment scans in a single month as OpsAI adoption reaches across dispatch, the field...

Technicians ran more than 100,000 equipment scans in a single month as OpsAI adoption reaches across dispatch, the field...
Anglais